While presently many clinical data exist on the separate beneficial effects of GLP-1 RAs on NASH resolution and atherosclerosis development and progression, there is a lack of clinical trials for the evaluation of the simultaneous effectiveness of these drugs in patients suffering from both NASH and atherosclerosis. Here, GLP1R is linked to metabolic dysfunction-associated steatohepatitis.